Cipher Pharma (CPHR) Announces Acquisition of INNOCUTIS Holdings in $45.5M Cash Deal
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/26/2024
- Wall Street stocks fall as weak GDP growth spreads rate-cut gloom
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil settles higher as weak U.S. economic growth offset by supply concerns
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Union Pacific beats profit estimates on stronger pricing, resumes share buyback
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hertz Global (HTZ) misses earnings expectations as fleet costs weigh
- Teladoc (TDOC) Misses Q1 EPS by 3c, offers outlook
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
Cipher Pharmaceuticals announces U.S. commercial entry through acquisition of INNOCUTIS
April 13, 2015 8:50 AM EDTAccelerates development of a leading North American dermatology company Adds U.S. commercial infrastructure for our acquisition/in-licensing activities Raises US$100 million Senior Notes to finance acquisition and future growth
MISSISSAUGA, ON, April 13, 2015 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX: CPH) ("Cipher" or "the Company") today announced that it has acquired INNOCUTIS Holdings LLC ("INNOCUTIS"), a privately held specialty dermatology company, for US$45.5 million in cash. All financial references are in U.S. dollars unless otherwise... More
